Biodesix BDSX Stock
Biodesix Price Chart
Biodesix BDSX Financial and Trading Overview
| Biodesix stock price | 18.8 USD |
| Previous Close | 16.81 USD |
| Open | 17.06 USD |
| Bid | 12.84 USD x 200 |
| Ask | 21.45 USD x 200 |
| Day's Range | 16.68 - 18.22 USD |
| 52 Week Range | 5 - 20.21 USD |
| Volume | 56.4K USD |
| Avg. Volume | 64.43K USD |
| Market Cap | 179.67M USD |
| Beta (5Y Monthly) | 0.593 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.96 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.6 USD |
BDSX Valuation Measures
| Enterprise Value | 223.38M USD |
| Trailing P/E | N/A |
| Forward P/E | -78.86364 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.8697271 |
| Price/Book (mrq) | 19.192478 |
| Enterprise Value/Revenue | 2.325 |
| Enterprise Value/EBITDA | -11.355 |
Trading Information
Biodesix Stock Price History
| Beta (5Y Monthly) | 0.593 |
| 52-Week Change | 215.45% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 20.21 USD |
| 52 Week Low | 5 USD |
| 50-Day Moving Average | 14.08 USD |
| 200-Day Moving Average | 10.85 USD |
BDSX Share Statistics
| Avg. Volume (3 month) | 64.43K USD |
| Avg. Daily Volume (10-Days) | 65.52K USD |
| Shares Outstanding | 10.36M |
| Float | 4.47M |
| Short Ratio | 1.36 |
| % Held by Insiders | 41.92% |
| % Held by Institutions | 38.75% |
| Shares Short | 106.46K |
| Short % of Float | 1.79% |
| Short % of Shares Outstanding | 1.02% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -33.25% |
| Operating Margin (ttm) | -25.81% |
| Gross Margin | 81.66% |
| EBITDA Margin | -20.47% |
Management Effectiveness
| Return on Assets (ttm) | -17.48% |
| Return on Equity (ttm) | -316.53% |
Income Statement
| Revenue (ttm) | 96.1M USD |
| Revenue Per Share (ttm) | 11.81 USD |
| Quarterly Revenue Growth (yoy) | 42.29% |
| Gross Profit (ttm) | 78.48M USD |
| EBITDA | -19673000 USD |
| Net Income Avi to Common (ttm) | -31957000 USD |
| Diluted EPS (ttm) | -3.96 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 25.57M USD |
| Total Cash Per Share (mrq) | 2.53 USD |
| Total Debt (mrq) | 73.57M USD |
| Total Debt/Equity (mrq) | 805.61 USD |
| Current Ratio (mrq) | 2.824 |
| Book Value Per Share (mrq) | 0.904 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -24837000 USD |
| Levered Free Cash Flow (ttm) | -13779875 USD |
Profile of Biodesix
| Country | United States |
| State | CO |
| City | Louisville |
| Address | 919 West Dillon Road |
| ZIP | 80027 |
| Phone | 303 417 0500 |
| Website | https://www.biodesix.com |
| Industry | Diagnostics & Research |
| Sector(s) | Healthcare |
| Full Time Employees | 334 |
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Q&A For Biodesix Stock
What is a current BDSX stock price?
Biodesix BDSX stock price today per share is 18.8 USD.
How to purchase Biodesix stock?
You can buy BDSX shares on the Tech Market Middle exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Biodesix?
The stock symbol or ticker of Biodesix is BDSX.
Which industry does the Biodesix company belong to?
The Biodesix industry is Diagnostics & Research.
How many shares does Biodesix have in circulation?
The max supply of Biodesix shares is 10.36M.
What is Biodesix Price to Earnings Ratio (PE Ratio)?
Biodesix PE Ratio is now.
What was Biodesix earnings per share over the trailing 12 months (TTM)?
Biodesix EPS is -3.96 USD over the trailing 12 months.
Which sector does the Biodesix company belong to?
The Biodesix sector is Healthcare.
Biodesix BDSX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25476.64 USD — |
-0.43
|
12.69B USD — | 25354.66 USD — | 25840.56 USD — | — - | 12.69B USD — |
|
US Tech Global Market Composite
NQGM
US
|
2295.4 USD — |
-0.65
|
— — | 2291.88 USD — | 2327.27 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1203.67 USD — |
+1.6
|
— — | 1192.12 USD — | 1213.64 USD — | — - | — — |
- {{ link.label }} {{link}}